BUSINESS

• Recomodulin Fails to Hit Primary Goal in PIII for Severe Sepsis with Coagulopathy: Asahi Kasei
  August 3, 2018

• Eisai Neurology Chief Shows Eagerness on Alzheimer’s Combination Trials
  August 2, 2018

• AstraZeneca’s AI Translation System Could Bring Huge Impact If Materialized: Japan R&D Chief
  August 2, 2018

• Opdivo Sales Up 15% in April-June: Ono
  August 2, 2018

• Daiichi Sankyo’s FLT3 Inhibitor Grabs FDA’s Breakthrough Therapy Status
  August 2, 2018

• Kyowa Kirin Hopeful of PIII Study of Sakigake Designated DKD Treatment: President
  August 2, 2018

• Kyorin Awards Spanish Pharma Rights to Uritos in Latin America
  August 2, 2018

• Rxulti Gets European Approval for Schizophrenia: Otsuka/Lundbeck
  August 1, 2018

• Takeda Completes TiGenix Acquisition
  August 1, 2018

• Lenvima-Keytruda Combo Bags FDA’s Breakthrough Status for Endometrial Carcinoma
  August 1, 2018

• Kyowa Hakko Kirin to Be Renamed Kyowa Kirin in July 2019
  August 1, 2018

• Kyowa Kirin Says It’s Steadily Pursuing Nesp Authorized Biosimilar Program, but Silent on Details
  August 1, 2018

• Kyowa Kirin Sales Sag 2.8% but Net Profit Jumps on Capital Gains
  August 1, 2018

• Daiichi Sankyo Offloading 41 Off-Patent Drugs to Alfresa as It Sharpens Focus on Oncology
  August 1, 2018

• Takeda Integration Team Prepping for Shire Takeover: Weber
  August 1, 2018

• AI in Pharma - 2: Daiichi Sankyo Looks to Set Competitors Apart with Efficient Call Center
  August 1, 2018

• Otsuka’s Guadecitabine Misses Primary Targets in Treatment-Naïve AML Patients in PIII
  August 1, 2018

• Lonasen Patch Formulation Filed in Japan: Sumitomo Dainippon, Nitto Denko
  August 1, 2018

• Eisai Grants Rights for Lorcaserin to Taiwan Biotech in China
  August 1, 2018

• ASKA, Laboratoire HRA Strike Deal for IP Rights to Uterine Fibroid Treatment
  August 1, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 376
• 377
• 378
• 379
• 380
• 381
• 382
• 383
• 384
• …
• Next ›
• 最終 »